TB-500 is under FDA advisory review in July 2026, and FDA staff documents recommend caution because human safety and effectiveness data are limited
Research-grade peptides are intended for laboratory research only, may contain impurities or inconsistent dosing, lack proper quality control, and carry legal and safety concerns for human use
It is derived from a partial sequence of human gastric juice protein BPC, and it carries no post-translational modifications or metal-binding requirements
Maintenance phase (weeks 5+): Reduced frequency to 3-5 times per week, with adjusted dosages
Common mild side effects: injection site soreness (1224 hours, resolves without treatment), brief warmth or flushing immediately after injection, occasional acne with regular use